Status:

RECRUITING

ctDNA Monitoring in Patients With HCC and mCRC

Lead Sponsor:

Medical University of Warsaw

Collaborating Sponsors:

Medical Research Agency, Poland

Conditions:

HCC - Hepatocellular Carcinoma

Colorectal Cancer Metastatic

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

"Liquid biopsy" is a collective term that refers to the analysis of cancer-derived biomarkers isolated from the biological fluids of cancer patients. The analysis of these blood components can be used...

Detailed Description

Health problem Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. It is estimated that it accounts for 80-90% all cases of liver cancer. Liver cancer is one of the...

Eligibility Criteria

Inclusion

  • age 18-75 years of both sexes;
  • patients with synchronous or metachronous metastases of colorectal cancer limited to the liver after complete removal of the primary lesion from the intestine qualified for liver resection or transplantation;
  • or patients with resectable or unresectable HCC scheduled for liver resection or transplantation
  • no history of other cancers;
  • negative virological status in the case of mCRC;
  • In the case of mCRC - patient after any type of liver surgery (staged, ALPPS, multi-site resection)
  • Patient with or without neoadjuvant chemotherapy compatible with established adjuvant therapy

Exclusion

  • age under 18 and over 75;
  • pregnancy
  • patients with extrahepatic metastases visible in imaging studies;
  • metabolic and autoimmune diseases or chronic immunosuppressive treatment other than in the group of patients after liver transplantation due to HCC;
  • positive virological status, excluding the group of patients with HCC;
  • history of other cancer;
  • Chronic steroid therapy and diagnosed active autoimmune diseases
  • Patient after radiotherapy
  • Patient participating in other clinical trials of oncological and non-oncological drugs
  • Patients legally incapacitated

Key Trial Info

Start Date :

January 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 30 2028

Estimated Enrollment :

300 Patients enrolled

Trial Details

Trial ID

NCT07001085

Start Date

January 1 2025

End Date

April 30 2028

Last Update

June 3 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Medical University of Warsaw

Warsaw, Masovian Voivodeship, Poland, 02-091

ctDNA Monitoring in Patients With HCC and mCRC | DecenTrialz